Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.
Departamento de Farmacología, División de Ciencias de la Salud, Universidad de Quintana Roo, Quintana Roo, Mexico.
Front Immunol. 2021 Nov 18;12:737340. doi: 10.3389/fimmu.2021.737340. eCollection 2021.
Acute lymphoblastic leukemia (ALL) is a malignancy with high heterogeneity in its biological features and treatments. Although the overall survival (OS) of patients with ALL has recently improved considerably, owing to the application of conventional chemo-therapeutic agents, approximately 20% of the pediatric cases and 40-50% of the adult patients relapse during and after the treatment period. The potential mechanisms that cause relapse involve clonal evolution, innate and acquired chemoresistance, and the ability of ALL cells to escape the immune-suppressive tumor response. Currently, immunotherapy in combination with conventional treatment is used to enhance the immune response against tumor cells, thereby significantly improving the OS in patients with ALL. Therefore, understanding the mechanisms of immune evasion by leukemia cells could be useful for developing novel therapeutic strategies.
急性淋巴细胞白血病 (ALL) 是一种生物学特征和治疗方法高度异质性的恶性肿瘤。尽管由于常规化疗药物的应用,ALL 患者的总体生存率 (OS) 最近有了显著提高,但约 20%的儿科病例和约 40-50%的成年患者在治疗期间和治疗后复发。导致复发的潜在机制包括克隆进化、先天和获得性化疗耐药以及 ALL 细胞逃避免疫抑制肿瘤反应的能力。目前,免疫疗法与常规治疗联合使用,以增强针对肿瘤细胞的免疫反应,从而显著提高 ALL 患者的 OS。因此,了解白血病细胞免疫逃逸的机制可能有助于开发新的治疗策略。